Launch of New Drug Discovery Open Innovation Platform
One of the world’s most prominent pharmaceutical companies, AstraZeneca plc has launched a new open innovation platform that it says will make it easier for scientists all over the world to access the organisation’s OI projects.
With goals of new drugs, faster development times and lower costs, the pharmaceutical industry is keenly embracing open innovation. The pipeline has to be continually replenished so R&D output needs to be ramped up, something that many companies feel they now cannot do on their own.
AstraZeneca’s core therapeutic areas are oncology, cardiovascular and metabolic disease and respiratory and autoimmune diseases. To help it speed up research in these areas the new open innovation platform consists of numerous components. They include:
- Target Innovation – a compound library for users to validate novel drug targets.
- New Molecule Profiling – exploring the properties and therapeutic potentials of new compounds.
- R & D Challenges – presenting the crowd with key research and development hurdles and rewarding innovative solutions.
- Suggestion Box – a good old-fashioned way for interested parties to submit ideas, technologies and solutions that fit outside the platform’s other open innovation offerings.
Opening up the Research Environment
Upon the launch of the platform, Mene Pangalos, Executive Vice-President, Innovative Medicines and Early Development at AstraZeneca, said:
“To push the boundaries of science and deliver new medicines to patients, we need to create a more permeable research environment, collaborating with academia, industry and government. Discovery of good science requires us all to work in more open and creative ways.”
To explore the open innovation platform, including more details of AstraZeneca’s OI projects and guidelines, click here.
Add your Comment
[LOGIN FIRST] if you're already a member.fields are required.